ClinicalTrials.gg
RecruitingNCT07542704Updated Nov 3, 2026

A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

A Phase 1 interventional study of KQB368 in Advanced Solid Tumors, Colorectal Cancer (CRC) and Non-Small Cell Lung Cancer, sponsored by Kumquat Biosciences Inc.. Recruiting at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Kumquat Biosciences Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Nov 3, 2026Now RecruitingFirst site in United States+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 2,341 studies in Colorectal Neoplasms with a site in United States — 417 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
1,121st of 1,933
48 · median 64
Started
2026
with 118 others
Phase 1
551 of 2,341
100 open now
Primary completion
2029-12
later than 567 of 627 live
Registered
2,277th of 2,341
by date

Among the 2,341 studies in Colorectal Neoplasms with a site in United States, this one is the 1,121st largest by planned enrollment of the 1,933 interventional ones that give a count, is one of 119 that started in 2026, is one of 551 in phase 1, reaches primary completion later than 567 of the 627 other live ones, and was the 2,277th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

417 of the 2,341 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

412 more — sign in →

All 417 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,341 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to learn if KQB368 works to treat advanced solid malignancies in adults. The study will also learn about the safety of KQB368. The main questions the study aims to answer are:

  • What is the safe dose of KQB368 as a monotherapy?
  • Does KQB368 decrease the size of the tumor?
  • What happens to KQB368 in the body?

Participants will:

  • Take KQB368 orally daily in 21-day cycles
  • Return to the study site about 7 times in the first 5 weeks, and then once at the beginning of every 21-day cycle after that
03

Conditions studied

  • Advanced Solid Tumors
  • Colorectal Cancer (CRC)
  • Non-Small Cell Lung Cancer
  • Uterine Cancer
  • KRAS G12C Mutations
  • KRAS G12S Mutations

Keywords

  • KQB368
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • confirmed diagnosis of a solid tumor
  • with either a KRAS G12C or KRAS G12S mutation
  • Unresectable or disease
  • No available treatment with curative intent
  • Adequate organ function
  • per v1.1
  • Must be able to swallow with no GI condition that prevents absorption
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Monotherapy Dose Escalation

    Drug: KQB368

Interventions

  • DrugKQB368

    Oral KQB368

06

What researchers measure

Primary outcomes

  1. Primary Objective

    Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities. Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of AEs, SAEs, and DLTs, from first dose of study treatment to 30 days after last dose of study treatment.

    Time frame: Up to 44 months

Secondary outcomes

  1. Objective response rate (ORR)

    Evaluate efficacy of study treatment, as measured by Objective Response Rate (ORR) using Response Evaluation Criteria (RECISTv1.1). Objective response is the proportion of subjects that experience confirmed complete response (CR) or partial response (PR) based on RECIST v1.1 during the time period from first dose of study treatment until last dose.

    Time frame: Up to 44 months

  2. Overall survival (OS)

    Evaluate efficacy of study treatment characterized by OS. Overall survival is defined as the time from start of treatment to death.

    Time frame: Up to 44 months

  3. Duration of response (DOR)

    Duration of response is defined as the time from date of the first documentation of objective tumor response (CR or PR) based on RECIST v1.1 to the first documentation of either PD or death due to any cause, whichever occurs first.

    Time frame: Up to 44 months

  4. Time to response (TTR)

    Time to response is defined as time from first dose of study treatment to date of first documentation of objective tumor response (CR or PR) based on RECIST v1.1.

    Time frame: Up to 44 months

  5. Disease control rate (DCR)

    Disease control rate is the proportion of subjects that experience confirmed complete response (CR), partial response (PR), or stable disease based on RECIST v1.1 during the time period from first dose of study treatment until last dose.

    Time frame: Up to 44 months

  6. Progression-free survival (PFS)

    Progression-free survival is defined as the time from enrollment to the date of Progressive Disease (PD) based on RECIST v1.1 or death due to any cause, whichever occurs first.

    Time frame: Up to 44 months

  7. Area under the concentration-time curve (AUC)

    Time frame: Up to 44 months

  8. Maximum plasma concentration (Cmax)

    Time frame: Up to 44 months

  9. Time to maximum plasma concentration (tmax)

    Time frame: Up to 44 months

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2029, 43 months after the start.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 43 months is close to that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 21, 2026
StartActual
May 27, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 3, 2026
Sites
14 sites added — first site in United States
Show 14 added (14 United States)
  • START Los Angeles · Los Angeles, United States
  • Massachusetts General Hospital · Boston, United States
  • Karmanos Cancer Institute · Detroit, United States
  • John Theurer Cancer Center at Hackensack UMC · Hackensack, United States
  • Memorial Sloan Kettering Cancer Center · New York, United States
  • UH Cleveland Medical Center · Cleveland, United States
  • Providence Cancer Institute · Portland, United States
  • Fox Chase Cancer Center · Philadelphia, United States
  • SCRI Oncology Partners · Nashville, United States
  • NEXT Oncology Austin · Austin, United States
  • START Dallas Fort Worth · Dallas, United States
  • START San Antonio · San Antonio, United States
  • University of Utah - Huntsman Cancer Institute · Salt Lake City, United States
  • NEXT Oncology Virginia · Fairfax, United States
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Not yet recruiting→Recruiting
    14 sites added — first site in United States
    Show 14 added (14 United States)
    • START Los Angeles · Los Angeles, United States
    • Massachusetts General Hospital · Boston, United States
    • Karmanos Cancer Institute · Detroit, United States
    • John Theurer Cancer Center at Hackensack UMC · Hackensack, United States
    • Memorial Sloan Kettering Cancer Center · New York, United States
    • UH Cleveland Medical Center · Cleveland, United States
    • Providence Cancer Institute · Portland, United States
    • Fox Chase Cancer Center · Philadelphia, United States
    • SCRI Oncology Partners · Nashville, United States
    • NEXT Oncology Austin · Austin, United States
    • START Dallas Fort Worth · Dallas, United States
    • START San Antonio · San Antonio, United States
    • University of Utah - Huntsman Cancer Institute · Salt Lake City, United States
    • NEXT Oncology Virginia · Fairfax, United States
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07542704
Lead sponsor
Kumquat Biosciences Inc.
Collaborators
Worldwide Clinical Trials
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
May 27, 2026
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Kumquat Clinical Development Telephone
Contact
kumquatstudies@kumquatbio.com
858.214.2700

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion